National Institute on Deafness and Other Communication Disorders (NIDCD)
Phase 3
1999-06-01
Many drugs used to treat autism target specific symptoms, such as hyperactivity and
aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction
and communication. This study will evaluate two forms of the drug secretin for the treatment
of core autistic symptoms.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 3
1999-06-01
Many drugs used to treat autism target specific symptoms, such as hyperactivity and
aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction
and communication. This study will evaluate two forms of the drug secretin for the treatment
of core autistic symptoms.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
